Genprex, Inc. (GNPX) - Dilution Analysis

10-Q filing | 9.0M shares outstanding

10-K filing | 3.3M shares outstanding

S-1/A filing: This S-1/A filing from 2025-11-26 details an offering of common stock by selling stockholders, with up to 1,280,088 shares available upon exercise of warrants.

8-K filing: Genprex, Inc. previously sold 796,065 shares of its common stock for aggregate gross proceeds of $14,796,375 under the Sales Agreement pursuant to the Prior Prospectuses. ($14.8M proceeds)

S-1 filing: This is an S-1 filing detailing an offering of common stock by selling stockholders, issuable upon exercise of warrants.

8-K filing: Genprex, Inc. entered into a securities purchase agreement to sell 243,622 shares of common stock at $11.21 per share in a registered direct offering and issue warrants exercisable for up to 487,244 shares in a concurrent private placement, and also implemented a 1-for-50 reverse stock split. ($2.73M proceeds)

8-K filing: Stock split 1-for-50 | Outstanding: 24,154,348 → 1,004,326

8-K filing: Genprex, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for up to $12.5 million in shares of common stock, and issued 1,186,859 commitment shares to Lincoln Park in consideration for its commitment to purchase shares under the purchase agreement.

S-1 filing: This S-1 filing relates to the resale of up to 15,000,000 shares of common stock by Lincoln Park Capital Fund, LLC, which may be issued pursuant to a purchase agreement. The company may receive up to $12.5 million in gross proceeds from sales of common stock to Lincoln Park.

S-1 filing: The company is filing an S-1 to offer shares of common stock, pre-funded warrants, and warrants for a total proposed amount of $8,000,000, with WestPark Capital, Inc. acting as the sole placement agent.

10-Q filing | 24.2M shares outstanding

10-K filing | 10.9M shares outstanding

10-Q filing | 5.5M shares outstanding

10-Q filing | 2.6M shares outstanding

10-Q filing | 1.9M shares outstanding

10-K filing | 1.4M shares outstanding

8-K filing: Genprex, Inc. entered into a securities purchase agreement for a registered direct offering of common stock, pre-funded warrants, and warrants, with an expected closing on or about March 21, 2024, and net proceeds of approximately $5.8 million intended for working capital and general corporate purposes.

8-K filing: Stock split 1-for-40 | Outstanding: 57,805,639 → 1,445,140

10-Q filing | 57.8M shares outstanding

10-Q filing | 52.0M shares outstanding

8-K filing: Genprex, Inc. entered into a securities purchase agreement to issue and sell 7,425,744 shares of common stock and warrants to accredited healthcare-focused institutional investors at a price of $1.01 per share and warrant, with net proceeds expected to be approximately $6.7 million for working capital and general corporate purposes. ($7.5M proceeds)

10-Q filing | 49.5M shares outstanding

S-3 filing: Genprex, Inc. is offering common stock, preferred stock, debt securities, subscription rights, and/or units, with an aggregate offering price not to exceed $200,000,000.

10-K filing | 48.0M shares outstanding

8-K filing: Genprex, Inc. entered into a securities purchase agreement to issue and sell 3,809,524 shares of common stock and warrants to purchase 3,809,524 shares of common stock in a registered direct offering, with gross proceeds expected to be approximately $4.0 million. ($4.0M proceeds)

10-Q filing | 48.0M shares outstanding

10-Q filing | 47.9M shares outstanding

10-Q filing | 47.9M shares outstanding

10-K filing | 47.9M shares outstanding

10-Q filing | 47.8M shares outstanding

10-Q filing | 47.5M shares outstanding

10-Q filing | 47.4M shares outstanding

10-K filing | 43.3M shares outstanding

8-K filing: Genprex, Inc. entered into a securities purchase agreement to issue and sell 4,000,000 shares of common stock at $6.25 per share in a registered direct offering, with expected net proceeds of approximately $23.2 million.

8-K filing: Genprex, Inc. entered into a securities purchase agreement to issue and sell 3,116,884 shares of common stock at $3.85 per share in a registered direct offering, expecting net proceeds of approximately $11.1 million for working capital and general corporate purposes. ($12.0M proceeds)

10-Q filing | 39.6M shares outstanding

10-Q filing | 38.9M shares outstanding

S-3/A filing: The company may offer and sell, from time to time, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $200,000,000.

S-3 filing: GNPX filed an S-3 form on 2020-06-12 for a combination offering of common stock, preferred stock, and debt securities, with a total proposed amount not exceeding $200,000,000.

8-K filing: Genprex, Inc. announces the exercise of warrants by institutional investors and placement agent designees, resulting in the issuance of 5,591,435 shares of common stock and receipt of $2.5 million in cash.

S-1/A filing: The filing details the sale of common stock in a registered direct offering, the issuance of warrants to investors and a placement agent, and the issuance of a warrant to a related party.

10-Q filing | 32.9M shares outstanding

8-K filing: Genprex, Inc. issued a warrant to Cancer Revolution, LLC to purchase 500,000 shares of common stock at an exercise price of $2.27 per share in conjunction with services provided to the Company.

10-K filing | 32.8M shares outstanding

8-K filing: Genprex, Inc. amended stock option agreements with directors and granted stock options to new board members under the 2018 Equity Incentive Plan.

8-K filing: Genprex, Inc. issued shares of common stock to consultants and granted stock options to service providers and employees.

8-K filing: Genprex, Inc. entered into a securities purchase agreement to issue and sell 5,000,000 shares of its common stock at a price of $3.50 per share in a registered direct offering, with expected net proceeds of approximately $16 million. ($17.5M proceeds)

8-K filing: Genprex, Inc. entered into a securities purchase agreement to issue and sell 7,620,000 shares of common stock at $1.05 per share in a registered direct offering, with expected net proceeds of approximately $7.2 million for working capital and general corporate purposes. Placement agents received an aggregate cash fee of $640,080.

8-K filing: Genprex, Inc. entered into a securities purchase agreement to issue and sell 961,000 shares of common stock at $0.24 per share in a registered direct offering, with the closing anticipated on January 21, 2020, and net proceeds expected to be approximately $200,000 for working capital and general corporate purposes.

8-K filing: David E. Friedman and Robert W. Pearson were granted options to purchase common stock of the Company in lieu of cash compensation.